Magalhães, Pedro V (2015) Clinical question: What are the benefits and harms of buprenorphine maintenance versus placebo or methadone maintenance in people with opioid dependence? Cochrane Clinical Answers, https://doi.org/10.1002/cca.538.
External website: https://www.cochranelibrary.com/cca/doi/10.1002/cc...
Buprenorphine, a partial opioid agonist, has pharmacological features, including safety at overdose and ease of use, which make it an interesting alternative to methadone for those with heroin use disorders. However, buprenorphine maintenance, although effective compared with placebo, was inferior to methadone in retaining people in treatment. There were no clear differences between the drugs on the other primary outcomes (drug use, safety, criminal activity).
B Substances > Opioids (opiates)
B Substances > Opioids (opiates) > Opioid product
B Substances > Opioids (opiates) > Opioid product > Buprenorphine / Suboxone
B Substances > Opioids (opiates) > Opioid product > Methadone
HJ Treatment or recovery method > Substance disorder treatment method
HJ Treatment or recovery method > Substance disorder treatment method > Substance disorder drug therapy (pharmacological treatment)
HJ Treatment or recovery method > Substance disorder treatment method > Substance replacement method (substitution) > Opioid agonist treatment (methadone maintenance / buprenorphine)
HJ Treatment or recovery method > Treatment outcome
J Health care, prevention, harm reduction and treatment > Patient / client care management
N Communication, information and education > Recommendations > Practice / clinical guidelines
VA Geographic area > International
Repository Staff Only: item control page